Lonza is expanding its early-phase small-molecule manufacturing facility in Nansha, China, to help meet the demands of customers globally. A new cGMP kilo lab and an additional small-scale train have been added to the site’s existing small-scale trains for clinical material, three large-scale API trains for metric tons, and cGMP laboratories to meet gram-scale requirements.
Lonza says it has been manufacturing small molecules in China since 1996. “This investment speeds our efforts to establish the Lonza Nansha site as a standard-of-quality to serve our global customer base for all material needs from gram-scale to metric tons,” comments Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With this expansion, Lonza’s FDA-approved Nansha site now offers a fully integrated end-to-end development and manufacturing solution for small molecules.”